It's hard for us at this point in time to say new patients on brand versus new patients to Rigel. We know they're all new patients to Rigel. But we think we are getting new patients to brand ...

These increases were partially offset by decreased research and development costs due to the timing of clinical trial activities related to R289, Rigel's dual IRAK 1/4 inhibitor program ...

For detailed financial analysis and expert insights on Rigel's growth prospects ... is currently approved in the United States under the brand name TAVALISSE® for treating adult patients with ...

Several research firms have recently issued reports on RIGL. B. Riley increased their price objective on shares of Rigel Pharmaceuticals from $17.00 to $27.00 and gave the stock a “neutral ...

On March 6, 2025, Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), a company specializing in pharmaceutical preparations with a market capitalization of $347 million and impressive revenue growth of 55% ...

A look at the shareholders of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) can tell us which group is most powerful. We can see that institutions own the lion's share in the company with 57% ownership.

SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to ...

(RTTNews) - Rigel Pharmaceuticals Inc. (RIGL) released earnings for its fourth quarter that increased from the same period last year The company's bottom line came in at $14.34 million, or $0.80 ...